Glutamate transporter GLT-1 as a therapeutic target for substance use disorders

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 6, 2015, Pages 745-756

  Roberts Wolfe, Douglas J ^a   Kalivas, Peter W ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Accumbens; Addiction; Ceftriaxone; Excitatory amino acid transporter 2; Glutamate; Glutamate transport; Glutamate transporter 1; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; AMPHETAMINE; CANNABINOID; CEFTRIAXONE; CLAVULANIC ACID; COCAINE; DOPAMINE TRANSPORTER; GLUTAMIC ACID; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; METHAMPHETAMINE; MORPHINE; NALOXONE; NALTREXONE; NICOTINE; OPIATE; PROPENTOFYLLINE; VESICULAR GLUTAMATE TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; NEUROTRANSMITTER UPTAKE INHIBITOR;

ADDICTION; ARTICLE; DOWN REGULATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; DRUG TARGETING; DRUG TOLERABILITY; HIPPOCAMPUS; HUMAN; NONHUMAN; NUCLEUS ACCUMBENS; NUCLEUS ACCUMBENS CORE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; ANIMAL; METABOLISM; SUBSTANCE-RELATED DISORDERS;

ACETYLCYSTEINE; ANIMALS; CEFTRIAXONE; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; SUBSTANCE-RELATED DISORDERS;

EID: 84934764092     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150529144655     Document Type: Article

References (108)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291(10): 1238-45.
2. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998; 93(4): 515-32.
3. Dawson DA, Goldstein RB, Grant BF. Rates and correlates of relapse among individuals in remission from DSM-IV alcohol dependence: a 3-year follow-up. Alcohol Clin Exp Res 2007; 31(12): 2036-45.
4. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008; 75(1): 218-65.
5. Kenny PJ, Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 2004; 25(5): 265-72.
6. Pomierny-Chamiolo L, Rup K, Pomierny B, Niedzielska E, Kalivas PW, Filip M. Metabotropic glutamatergic receptors and their ligands in drug addiction. Pharmacol Ther 2014; 142(3): 281-305.
7. Bisaga A, Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend 2000; 59(1): 1-15.
8. Conrad KL, Tseng KY, Uejima JL, et al. Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature 2008; 454(7200): 118-21.
9. Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 2007; 31(5): 775-82.
10. Yoon JH, Newton TF, Haile CN, et al. Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine-and nicotine-dependent volunteers. Addict Behav 2013; 38(2): 1518-26.
11. Kampman KM, Dackis C, Lynch KG, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006; 85(2): 129-37.
12. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009; 10(8): 561-72.
13. McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaineinduced reinstatement of drug-seeking behavior. J Neurosci 2003; 23(8): 3531-7.
14. LaLumiere RT, Kalivas PW. Glutamate release in the nucleus accumbens core is necessary for heroin seeking. J Neurosci 2008; 28(12): 3170-7.
15. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65(1): 1-105.
16. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319(24): 1557-62.
17. Lauterburg BH, Corcoran GB, Mitchell JR. Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Investig 1983; 71(4): 980-91.
18. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005; 433(7021): 73-7.
19. Berry JD, Shefner JM, Conwit R, et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PloS One 2013; 8(4): e61177.
20. Lee SG, Su ZZ, Emdad L, et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem 2008; 283(19): 13116-23.
21. Knackstedt LA, Melendez RI, Kalivas PW. Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol Psychiatry 2010; 67(1): 81-4.
22. Trantham-Davidson H, LaLumiere RT, Reissner KJ, Kalivas PW, Knackstedt LA. Ceftriaxone normalizes nucleus accumbens synaptic transmission, glutamate transport, and export following cocaine self-administration and extinction training. J Neurosci 2012; 32(36): 12406-10.
23. Reissner KJ, Gipson CD, Tran PK, Knackstedt LA, Scofield MD, Kalivas PW. Glutamate transporter GLT-1 mediates Nacetylcysteine inhibition of cocaine reinstatement. Addict Biol 2014; 20(2): 316-23.
24. Fischer KD, Houston AC, Rebec GV. Role of the major glutamate transporter GLT1 in nucleus accumbens core versus shell in cueinduced cocaine-seeking behavior. J Neurosci 2013; 33(22): 9319-27.
25. Fischer-Smith KD, Houston AC, Rebec GV. Differential effects of cocaine access and withdrawal on glutamate type 1 transporter expression in rat nucleus accumbens core and shell. Neuroscience 2012; 210: 333-9.
26. Parikh V, Naughton SX, Shi X, et al. Cocaine-induced neuroadaptations in the dorsal striatum: glutamate dynamics and behavioral sensitization. Neurochem Int 2014; 75: 54-65.
27. Reissner KJ, Brown RM, Spencer S, Tran PK, Thomas CA, Kalivas PW. Chronic administration of the methylxanthine propentofylline impairs reinstatement to cocaine by a GLT-1-dependent mechanism. Neuropsychopharmacology 2014; 39(2): 499-506.
28. Sondheimer I, Knackstedt LA. Ceftriaxone prevents the induction of cocaine sensitization and produces enduring attenuation of cue and cocaine-primed reinstatement of cocaine-seeking. Behav Brain Res 2011; 225(1): 252-8.
29. Sari Y, Smith KD, Ali PK, Rebec GV. Upregulation of GLT1 attenuates cue-induced reinstatement of cocaine-seeking behavior in rats. J Neurosci 2009; 29(29): 9239-43.
30. Madayag A, Lobner D, Kau KS, et al. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. J Neurosci 2007; 27(51): 13968-76.
31. Amen SL, Piacentine LB, Ahmad ME, et al. Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocainedependent humans. Neuropsychopharmacology 2011; 36(4): 871-8.
32. Reichel CM, Moussawi K, Do PH, Kalivas PW, See RE. Chronic N-acetylcysteine during abstinence or extinction after cocaine selfadministration produces enduring reductions in drug seeking. J Pharmacol Exp Ther 2011; 337(2): 487-93.
33. Moussawi K, Zhou W, Shen H, et al. Reversing cocaine-induced synaptic potentiation provides enduring protection from relapse. Proc Natl Acad Sci USA 2011; 108(1): 385-90.
34. LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm RJ. A double-blind placebo-controlled trial of Nacetylcysteine in the treatment of cocaine dependence. Am J Addict 2013; 22(5): 443-52.
35. LaRowe SD, Myrick H, Hedden S, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007; 164(7): 1115-7.
36. LaRowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006; 15(1): 105-10.
37. Mardikian PN, LaRowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(2): 389-94.
38. Shen HW, Scofield MD, Boger H, Hensley M, Kalivas PW. Synaptic glutamate spillover due to impaired glutamate uptake mediates heroin relapse. J Neurosci 2014; 34(16): 5649-57.
39. Tai YH, Tsai RY, Wang YH, et al. Amitriptyline induces nuclear transcription factor-kappaB-dependent glutamate transporter upregulation in chronic morphine-infused rats. Neuroscience 2008; 153(3): 823-31.
40. Xu NJ, Bao L, Fan HP, et al. Morphine withdrawal increases glutamate uptake and surface expression of glutamate transporter GLT1 at hippocampal synapses. J Neurosci 2003; 23(11): 4775-84.
41. Ozawa T, Nakagawa T, Shige K, Minami M, Satoh M. Changes in the expression of glial glutamate transporters in the rat brain accompanied with morphine dependence and naloxone-precipitated withdrawal. Brain Res 2001; 905(1-2): 254-8.
42. Fujio M, Nakagawa T, Sekiya Y, et al. Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine-and morphine-induced conditioned place preference in rats. Eur J Neurosci 2005; 22(11): 2744-54.
43. Ozawa T, Nakagawa T, Sekiya Y, Minami M, Satoh M. Effect of gene transfer of GLT-1, a glutamate transporter, into the locus coeruleus by recombinant adenoviruses on morphine physical dependence in rats. Eur J Neurosci 2004; 19(1): 221-6.
44. Zhou W, Kalivas PW. N-acetylcysteine reduces extinction responding and induces enduring reductions in cue-and heroininduced drug-seeking. Biol Psychiatry 2008; 63(3): 338-40.
45. Nakagawa T, Fujio M, Ozawa T, Minami M, Satoh M. Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice. Behav Brain Res 2005; 156(2): 233-9.
46. Sekiya Y, Nakagawa T, Ozawa T, Minami M, Satoh M. Facilitation of morphine withdrawal symptoms and morphineinduced conditioned place preference by a glutamate transporter inhibitor DL-threo-beta-benzyloxyaspartate in rats. Eur J Pharmacol 2004; 485(1-3): 201-10.
47. Rawls SM, Baron DA, Kim J. beta-Lactam antibiotic inhibits development of morphine physical dependence in rats. Behav Pharmacol 2010; 21(2): 161-4.
48. Rawls SM, Tallarida R, Robinson W, Amin M. The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats. Br J Pharmacol 2007; 151(7): 1095-102.
49. Rawls SM, Zielinski M, Patel H, Sacavage S, Baron DA, Patel D. Beta-lactam antibiotic reduces morphine analgesic tolerance in rats through GLT-1 transporter activation. Drug Alcohol Depend 2010; 107(2-3): 261-3.
50. Melendez RI, Hicks MP, Cagle SS, Kalivas PW. Ethanol exposure decreases glutamate uptake in the nucleus accumbens. Alcohol Clin Exp Res 2005; 29(3): 326-33.
51. Schreiber R, Freund WD. Glutamate transport is downregulated in the cerebral cortex of alcohol-preferring rats. Med Sci Monit 2000; 6(4): 649-52.
52. Devaud LL. Ethanol dependence has limited effects on GABA or glutamate transporters in rat brain. Alcohol Clin Exp Res 2001; 25(4): 606-11.
53. Sari Y, Sreemantula SN. Neuroimmunophilin GPI-1046 reduces ethanol consumption in part through activation of GLT1 in alcoholpreferring rats. Neuroscience 2012; 227: 327-35.
54. Qrunfleh AM, Alazizi A, Sari Y. Ceftriaxone, a beta-lactam antibiotic, attenuates relapse-like ethanol-drinking behavior in alcohol-preferring rats. J Psychopharmacol 2013; 27(6): 541-9.
55. Rao PS, Sari Y. Effects of ceftriaxone on chronic ethanol consumption: a potential role for xCT and GLT1 modulation of glutamate levels in male P rats. J Mol Neurosci 2014; 54(1): 71-7.
56. Sari Y, Sakai M, Weedman JM, Rebec GV, Bell RL. Ceftriaxone, a beta-lactam antibiotic, reduces ethanol consumption in alcoholpreferring rats. Alcohol Alcohol 2011; 46(3): 239-46.
57. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64(6): 468-75.
58. Bernardo M, Dodd S, Gama CS, et al. Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo controlled clinical trial. Acta Neuropsychiatr 2009; 21(5): 239-45.
59. Moreno C, Langlet P, Hittelet A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol 2010; 53(6): 1117-22.
60. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1781-9.
61. Gipson CD, Reissner KJ, Kupchik YM, et al. Reinstatement of nicotine seeking is mediated by glutamatergic plasticity. Proc Natl Acad Sci USA 2013; 110(22): 9124-9.
62. Knackstedt LA, LaRowe S, Mardikian P, et al. The role of cystineglutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 2009; 65(10): 841-5.
63. Lim DK, Kim HS. Chronic exposure of nicotine modulates the expressions of the cerebellar glial glutamate transporters in rats. Arch Pharm Res 2003; 26(4): 321-9.
64. Schroeder JA, Quick KF, Landry PM, Rawls SM. Glutamate transporter activation enhances nicotine antinociception and attenuates nicotine analgesic tolerance. NeuroReport 2011; 22(18): 970-3.
65. Alajaji M, Bowers MS, Knackstedt L, Damaj MI. Effects of the beta-lactam antibiotic ceftriaxone on nicotine withdrawal and nicotine-induced reinstatement of preference in mice. Psychopharmacology 2013; 228(3): 419-26.
66. Ramirez-Nino AM, D'Souza MS, Markou A. N-acetylcysteine decreased nicotine self-administration and cue-induced reinstatement of nicotine seeking in rats: comparison with the effects of N-acetylcysteine on food responding and food seeking. Psychopharmacology 2013; 225(2): 473-82.
67. Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res 2011; 17(4): 211-6.
68. McClure EA, Baker NL, Gray KM. Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents. Am J Drug Alcohol Abuse 2014; 40(4): 285-91.
69. Van Schooten FJ, Besaratinia A, De Flora S, et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol Biomarkers Prevent 2002; 11(2): 167-75.
70. Grant JE, Odlaug BL, Chamberlain SR, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry 2014; 75(1): 39-45.
71. McClure EA, Baker NL, Gipson CD, et al. An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. Am J Drug Alcohol Abuse 2015; 41(1): 52-6.
72. Shirai Y, Shirakawa O, Nishino N, Saito N, Nakai H. Increased striatal glutamate transporter by repeated intermittent administration of methamphetamine. Psychiatry Clin Neurosci 1996; 50(3): 161-4.
73. Sidiropoulou K, Chao S, Lu W, Wolf ME. Amphetamine administration does not alter protein levels of the GLT-1 and EAAC1 glutamate transporter subtypes in rat midbrain, nucleus accumbens, striatum, or prefrontal cortex. Brain Res Mol Brain Res 2001; 90(2): 187-92.
74. Del Arco A, Gonzalez-Mora JL, Armas VR, Mora F. Amphetamine increases the extracellular concentration of glutamate in striatum of the awake rat: involvement of high affinity transporter mechanisms. Neuropharmacology 1999; 38(7): 943-54.
75. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007; 47: 681-98.
76. Rasmussen B, Unterwald EM, Rawls SM. Glutamate transporter subtype 1 (GLT-1) activator ceftriaxone attenuates amphetamineinduced hyperactivity and behavioral sensitization in rats. Drug Alcohol Depend 2011; 118(2-3): 484-8.
77. Abulseoud OA, Miller JD, Wu J, Choi DS, Holschneider DP. Ceftriaxone upregulates the glutamate transporter in medial prefrontal cortex and blocks reinstatement of methamphetamine seeking in a condition place preference paradigm. Brain Res 2012; 1456: 14-21.
78. Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol 2010; 20(11): 823-8.
79. Castaldo P, Magi S, Gaetani S, et al. Prenatal exposure to the cannabinoid receptor agonist WIN 55, 212-2 increases glutamate uptake through overexpression of GLT1 and EAAC1 glutamate transporter subtypes in rat frontal cerebral cortex. Neuropharmacology 2007; 53(3): 369-78.
80. Gunduz O, Oltulu C, Ulugol A. Role of GLT-1 transporter activation in prevention of cannabinoid tolerance by the betalactam antibiotic, ceftriaxone, in mice. Pharmacol Biochem Behav 2011; 99(1): 100-3.
81. Gray KM, Watson NL, Carpenter MJ, Larowe SD. Nacetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 2010; 19(2): 187-9.
82. Roten AT, Baker NL, Gray KM. Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addict Behav 2013; 38(3): 1788-91.
83. Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabisdependent adolescents. Am J Psychiatry 2012; 169(8): 805-12.
84. McClure EA, Sonne SC, Winhusen T, et al. Achieving Cannabis Cessation-Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials 2014; 39(2): 211-23.
85. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamatemodulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62(6): 652-7.
86. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009; 66(7): 756-63.
87. Koob GF, Buck CL, Cohen A, et al. Addiction as a stress surfeit disorder. Neuropharmacology 2014; 76 Pt B: 370-82.
88. Swedo SE, Leonard HL. Trichotillomania. An obsessive compulsive spectrum disorder? Psychiatr Clin N Am 1992; 15(4): 777-90.
89. Thorlin T, Roginski RS, Choudhury K, et al. Regulation of the glial glutamate transporter GLT-1 by glutamate and delta-opioid receptor stimulation. FEBS Lett 1998; 425(3): 453-9.
90. Willuhn I, Burgeno LM, Groblewski PA, Phillips PE. Excessive cocaine use results from decreased phasic dopamine signaling in the striatum. Nat Neurosci 2014; 17(5): 704-9.
91. Liu S, Green CE, Lane SD, et al. The influence of dopamine betahydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study. Pharmacogenet Genom 2014; 24(7): 370-3.
92. Lievens JC, Salin P, Nieoullon A, Kerkerian-Le Goff L. Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum. J Neurochem 2001; 79(4): 893-902.
93. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329(5994): 959-64.
94. Wu X, Kihara T, Akaike A, Niidome T, Sugimoto H. PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes. Biochem Biophys Res Commun 2010; 393(3): 514-8.
95. Dakwar E, Levin F, Foltin RW, Nunes EV, Hart CL. The effects of subanesthetic ketamine infusions on motivation to quit and cueinduced craving in cocaine-dependent research volunteers. Biol Psychiatry 2014; 76(1): 40-6.
96. Featherstone RE, Liang Y, Saunders JA, Tatard-Leitman VM, Ehrlichman RS, Siegel SJ. Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiol Dis 2012; 47(3): 338-46.
97. Schroeder JA, Tolman NG, McKenna FF, et al. Clavulanic acid reduces rewarding, hyperthermic and locomotor-sensitizing effects of morphine in rats: a new indication for an old drug? Drug Alcohol Depend 2014; 142: 41-5.
98. Kong Q, Chang LC, Takahashi K, et al. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J Clin Investig 2014; 124(3): 1255-67.
99. Li Y, Sattler R, Yang EJ, et al. Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacology 2011; 60(7-8): 1168-75.
100. Uys JD, Knackstedt L, Hurt P, et al. Cocaine-induced adaptations in cellular redox balance contributes to enduring behavioral plasticity. Neuropsychopharmacology 2011; 36(12): 2551-60.
101. Wang HW, Yang W, Lu JY, et al. N-acetylcysteine administration is associated with reduced activation of NF-kB and preserves lung dendritic cells function in a zymosan-induced generalized inflammation model. J Clin Immunol 2013; 33(3): 649-60.
102. Oka S, Kamata H, Kamata K, Yagisawa H, Hirata H. Nacetylcysteine suppresses TNF-induced NF-kappaB activation through inhibition of IkappaB kinases. FEBS Lett 2000; 472(2-3): 196-202.
103. Kim SY, Jones TA. The effects of ceftriaxone on skill learning and motor functional outcome after ischemic cortical damage in rats. Restor Neurol Neurosci 2013; 31(1): 87-97.
104. Matos-Ocasio F, Hernandez-Lopez A, Thompson KJ. Ceftriaxone, a GLT-1 transporter activator, disrupts hippocampal learning in rats. Pharmacol Biochem Behav 2014; 122: 118-21.
105. Karaman I, Kizilay-Ozfidan G, Karadag CH, Ulugol A. Lack of effect of ceftriaxone, a GLT-1 transporter activator, on spatial memory in mice. Pharmacol Biochem Behav 2013; 108: 61-5.
106. Moussawi K, Pacchioni A, Moran M, et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci 2009; 12(2): 182-9.
107. Peters J, Kalivas PW. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine-and foodseeking behavior in rats. Psychopharmacology 2006; 186(2): 143-9.
108. Baker DA, McFarland K, Lake RW, et al. Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 2003; 6(7): 743-9.